Pharmacovigilance Risk Assessment Committee (PRAC)

PRAC is responsible for assessing all aspects of risk management of human medicines, including:

• the detection, assessment, minimisation and communication of the risk of adverse reactions, while taking the therapeutic effect of the medicine into account;
• design and evaluation of post-authorisation safety studies;
• pharmacovigilance audit.

Recommendations

PRAC provides recommendations on questions on pharmacovigilance and risk management systems, including the monitoring of their effectiveness, to the:

• Committee for Medicinal Products for Human Use (CHMP) for centrally authorised medicines and referral procedures;
• Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the use of a medicine in Member States;
• EMA secretariat, Management Board and European Commission, as applicable.

PRAC was formally established in line with the pharmacovigilance legislation which came into effect in 2012 to help strengthen the safety monitoring of medicines across Europe.